Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Oryzon secures €12 million through placement of new shares

Oryzon has issued 4,444,445 new ordinary shares at €2.70 each, raising €12 million without subscription rights. The issue price is around 12–14% below recent reference prices. The proceeds are intended to strengthen the balance sheet and primarily to finance the clinical development of Iadademstat for acute myeloid leukemia as well as ongoing programs in hematology and psychiatry. In addition, there is a subscription commitment from the Social Impact Fund (managed by COFIDES) for up to €25 million for future capital increases, subject to certain conditions. » Altro su de.investing.com
Oryzon Genomics receives FDA feedback on Phase‑III protocol for Vafidemstat

Oryzon Genomics has received written feedback from the FDA on the Phase‑III study protocol for Vafidemstat in borderline personality disorder. The comments concern study design, selection of endpoints and non‑clinical aspects; Oryzon plans to incorporate the recommendations and resubmit a revised protocol. The company is working with international clinical advisers and regulatory specialists on the revision and says it will provide further information after follow‑up discussions with the FDA. Other CNS studies are continuing on schedule in parallel, including the Phase‑IIb EVOLUTION study in schizophrenia. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2022, Oryzon Genomics ha già distribuito 0,26€ di dividendi. L'ultimo pagamento è avvenuto a marzo 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Oryzon Genomics ha registrato ricavi pari a 0,00€ e un utile netto di −164,92k€

(EUR)	giu 2026	YoY
Ricavi	0,00	100,00%
Utile lordo	−36,58k	100,76%
Utile netto	−164,92k	259,60%
EBITDA	−1,99M	670,47%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+220,20M€
Numero di azioni	77,59M
Massimo/minimo a 52 settimane	+2,88€ - +1,60€
Dividendi	No
Beta	0,45
Rapporto P/E	−91,54
Rapporto PEG	−1,57
Rapporto P/B	+1,85
Rapporto P/S	0,00

Profilo aziendale

Oryzon Genomics S.A., ein biopharmazeutisches Unternehmen in der klinischen Phase, beschäftigt sich mit der Entdeckung und Entwicklung von epigenetisch basierten Therapeutika für Patienten mit Krebs und ZNS-Erkrankungen. Zu den in der klinischen Phase befindlichen Präparaten gehören iadademstat (ORY-1001), ein selektiver LSD1-Inhibitor, der sich in Phase-II-Studien für die Onkologie befindet, und vafidemstat (ORY-2001), ein für das ZNS optimierter LSD1-Inhibitor, der sich in Phase-II-Studien für die Behandlung von ZNS- und psychiatrischen Erkrankungen befindet. Zu den Produktkandidaten gehört auch ORY-3001, ein LSD1-Inhibitor, der sich in der präklinischen Entwicklung für die Behandlung nicht-onkologischer Erkrankungen befindet. Das Unternehmen wurde im Jahr 2000 gegründet und hat seinen Sitz in Cornellà de Llobregat, Spanien.

Nome	Oryzon Genomics
CEO	Carlos Manuel Buesa Arjol
Sede centrale	Cornellà de Llobregat, ct Spagna
Sito web	oryzon.com
Quotazione in borsa	06/04/2022
Dipendenti	46